miRNA-34a is associated with docetaxel resistance in human breast cancer cells

Docetaxel is a chemotherapy drug to treat breast cancer, however as with many chemotherapeutic drugs resistance to docetaxel occurs in 50% of patients, and the underlying molecular mechanisms of drug resistance are not fully understood. Gene regulation through microRNAs (miRNA) has been shown to play an important role in cancer drug resistance. By directly targeting mRNA, miRNAs are able to inhibit genes that are necessary for signalling pathways or drug induced apoptosis rendering cells drug resistant. This study investigated the role of differential miRNA expression in two in vitro breast cancer cell line models (MCF-7, MDA-MB-231) of acquired docetaxel resistance. MiRNA microarray analysis identified 299 and 226 miRNAs altered in MCF-7 and MDA-MB-231 docetaxel-resistant cells, respectively. Docetaxel resistance was associated with increased expression of miR-34a and miR-141 and decreased expression of miR-7, miR-16, miR-30a, miR-125a-5p, miR-126. Computational target prediction revealed eight candidate genes targeted by these miRNAs. Quantitative PCR and western analysis confirmed decreased expression of two genes, BCL-2 and CCND1, in docetaxel-resistant cells, which are both targeted by miR-34a. Modulation of miR-34a expression was correlated with BCL-2 and cyclin D1 protein expression changes and a direct interaction of miR-34a with BCL-2 was shown by luciferase assay. Inhibition of miR-34a enhanced response to docetaxel in MCF-7 docetaxel-resistant cells, whereas overexpression of miR-34a conferred resistance in MCF-7 docetaxel-sensitive cells. This study is the first to show differences in miRNA expression, in particular, increased expression of miR-34a in an acquired model of docetaxel resistance in breast cancer. This serves as a mechanism of acquired docetaxel resistance in these cells, possibly through direct interactions with BCL-2 and CCND1, therefore presenting a potential therapeutic target for the treatment of docetaxel-resistant breast cancer.

[1]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[2]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[3]  T. Deguchi,et al.  MiR‐34a attenuates paclitaxel‐resistance of hormone‐refractory prostate cancer PC3 cells through direct and indirect mechanisms , 2010, The Prostate.

[4]  Sharon J. Diskin,et al.  A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene , 2008, Molecular Cancer Research.

[5]  Yi Tie,et al.  Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest , 2008, FEBS letters.

[6]  C. Kang,et al.  Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells , 2010, Technology in cancer research & treatment.

[7]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.

[8]  John S Mattick,et al.  Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7* , 2009, Journal of Biological Chemistry.

[9]  M. Pagano,et al.  Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. , 1994, Oncogene.

[10]  K. Tanabe,et al.  Modulation of tamoxifen sensitivity by antisense Bcl‐2 and trastuzumab in breast carcinoma cells , 2005, Cancer.

[11]  S. Noguchi.  Predictive factors for response to docetaxel in human breast cancers , 2006, Cancer science.

[12]  Peng Jin,et al.  Physiological identification of human transcripts translationally regulated by a specific microRNA. , 2005, Human molecular genetics.

[13]  Hyunsuk Shim,et al.  Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. , 2010, Biochemical pharmacology.

[14]  M. Gossen,et al.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.

[15]  Ping Zhang,et al.  Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line , 2006, BMC Cancer.

[16]  Donald C. Chang,et al.  The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function , 2007, Molecular biotechnology.

[17]  Y. Miyoshi,et al.  Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers , 2005, Breast cancer.

[18]  R. Callaghan,et al.  Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. , 2006, Current opinion in pharmacology.

[19]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[20]  I. Brown,et al.  Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells , 2004, Breast Cancer Research.

[21]  S. Eissa,et al.  Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. , 2000, Anticancer research.

[22]  Yasunori Fujita,et al.  Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. , 2008, Biochemical and biophysical research communications.

[23]  I. Brown,et al.  Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  S. Vranić,et al.  The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer. , 2004, Bosnian journal of basic medical sciences.

[25]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[26]  J. Bartek,et al.  Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. , 1995, Cancer research.

[27]  V. Tarasov,et al.  Differential Regulation of microRNAs by p53 Revealed by Massively Parallel Sequencing: miR-34a is a p53 Target That Induces Apoptosis and G1-arrest , 2007, Cell cycle.

[28]  C. Osborne,et al.  bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Yashiro,et al.  Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. , 2006, Oncology reports.

[30]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[31]  I. Brown,et al.  The FASEB Journal express article 10.1096/fj.04-3178fje. Published online June 9, 2005. Alterations of β-tubulin isotypes in breast cancer cells resistant to docetaxel , 2022 .

[32]  Lukyanova Ny,et al.  Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. , 2009 .

[33]  M. Itabashi,et al.  Expression of Bcl‐2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosis , 1997, Pathology international.

[34]  Bo Liu,et al.  MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. , 2009, Lung cancer.

[35]  Haoming Zhang,et al.  miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes , 2008, Nucleic acids research.

[36]  C. Chao,et al.  Expression patterns of cell cycle and apoptosis‐related genes in a multidrug‐resistant human colon carcinoma cell line , 2004, Scandinavian journal of gastroenterology.

[37]  L. Kastl,et al.  Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells. , 2010, International journal of oncology.

[38]  C. Sotiriou,et al.  Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. , 2004, Clinical breast cancer.

[39]  H. Heng,et al.  Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell Line , 2005, Clinical Cancer Research.

[40]  N. Kondo,et al.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. , 2009, Cancer research.

[41]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Reed,et al.  Different roles for cyclins D1 and E in regulation of the G1-to-S transition , 1995, Molecular and cellular biology.

[43]  Å. Borg,et al.  p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck , 2006, Acta oncologica.

[44]  Yi Tie,et al.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. , 2009, Cancer letters.

[45]  Peng Liu,et al.  miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation , 2009, Brain Research Bulletin.

[46]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Lorenzo Ferraro,et al.  Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. , 2010, The American journal of pathology.

[48]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[49]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Ng,et al.  Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis , 1999, Apoptosis.

[51]  J. Reed,et al.  Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells , 1997, Breast Cancer Research and Treatment.

[52]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[53]  G. Meister,et al.  Identification of Human microRNA Targets From Isolated Argonaute Protein Complexes , 2007, RNA biology.

[54]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.